http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-055630-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| filingDate | 2006-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80cf4625fcb0c0bcc500d584389691ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_817696cbdc9cc33bf60b77bc3c8053b2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f171f0b6704e8864db698660cc3a6d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e84d1d2f72eaef8bd8651d3be117809c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4006fab5036fdcce3ff1ebc260b8abf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7010b3831eda2939a4a8b0c9645cf2fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c46d4a1b9718641be3fb0b55bb4717a |
| publicationDate | 2007-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-055630-A1 |
| titleOfInvention | DERIVATIVES OF DIAZASPIRO AS ANTAGONISTS OF THE CCR8 RECEPTOR, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF RESPIRATORY DISEASES. |
| abstract | Processes for its preparation, pharmaceutical compositions containing them and their therapeutic use, in medicines for the treatment of respiratory diseases. Claim 1: A compound characterized in that it responds to the general formula (1) wherein B represents the group of formula (2); Ring D, together with the two C atoms of benzene to which it is fused, is a 5 or 6-membered non-aromatic ring containing one or two O atoms in the ring, and optionally containing a double CC bond between the two ring C atoms other than said benzene C atoms, the D ring being optionally substituted with one or more substituents independently selected from C1-6 alkyl, cycloalkyl, or phenyl (said phenyl being optionally substituted with one or more substituents independently selected from halogen, hydroxyl or C1-4 alkoxy), and also where when the D-ring is a non-aromatic 5-membered ring containing two O atoms in the ring that are arranged in 1, 3 , the D ring may be optionally substituted with the E group, wherein the group E together with a single C atom in the D ring represents a 4 to 8 membered cycloalkyl ring, such that the E group forms a str uctura spiro with ring D; w, x, y and z are independently 1, 2 or 3; each R represents a group independently selected from halogen or C1-4 alkyl; n is 0, 1 or 2; A represents a group selected from phenyl, a 5- or 6-membered heteroaromatic ring containing at least one heteroatom in the ring independently selected from N, O or S, or pyridine-N-oxide, each group being optionally substituted with one or more substituents independently selected from hydroxyl, -CN, halogen, oxo (= O), C1-6 aminoalkyl, C1-6 alkylamino-C1-6 alkyl, N, Ndi (C1-6) alkylamino-C1-6 alkyl , C1-6 alkoxy, C1-6 alkylcarbonyl, -NR1R2, -C (O) -NR3R4, -C1-6 alkenyl-C (O) -NR3R4, -C1-4 alkyl-C (O) -NR5R6, -NHSO2 -R7, -NHC (O) R8, -SO2NH2, carboxyl, carboxy-C1-6 alkyl, C1-6 alkoxycarbonyl, C1-4 alkoxycarbonyl-C1-4 alkyl, C3-6 cycloalkylamino, phenyl, pyridyl (said phenyl being and pyridyl also substituted with one or more groups independently selected from halogen, hydroxyl, carboxy or C1-4 alkyl), C1-6 alkyl or C3-6 cycloalkyl (said two substituents being C1-6 alkyl and C3-6 cycloalkyl also their optionally substituted with one or more substituents independently selected from halogen, hydroxyl, or -CN); or A represents a 9 to 10-membered bicyclic ring system that contains one or more ring heteroatoms independently selected from N, O or S and that is optionally substituted with one or more substituents independently selected from hydroxyl, - CN, halogen, oxo, C1-6 alkoxy, -NR9R10, carboxyl, or C1-6 alkyl; p is 0, 1 or 2; R1 and R2 each independently represent an atom of H, a C1-6 alkyl, C3-6 cycloalkyl or R1 and R2 together with the N atom to which they are attached form a hydantoin group or form a saturated heterocycle of 4 to 7 members, said heterocycle being optionally substituted with hydroxyl, C1-4 alkoxy, or C1-4 alkoxy-C1-4 alkyl; R3 and R4 each independently represents an atom of H, C1-6 alkyl, or C3-6 cycloalkyl, or R3 and R together with the N atom to which they are attached form a saturated heterocycle of 4 to 7 members, being said heterocycle optionally substituted with aminocarbonyl; R5 and R6 each independently represents an atom of H, C1-6 alkyl, or C3-6 cycloalkyl, or R5 and R6 together with the N atom to which they are attached form a saturated heterocycle of 4 to 7 members, being said heterocycle optionally substituted with aminocarbonyl; R7 represents C1-6 alkyl, or a saturated or unsaturated 6-membered ring, where the ring contains at least one N atom, the ring being optionally substituted with one or more substituents independently selected from halogen, oxo, C1-6 alkoxy, or C1-6 alkyl; R8 represents pyridine-N-oxide optionally substituted with one or more substituents independently selected from halogen, or C1-6 alkyl, or R8 represents C1-6 alkyl, C1-6 hydroxyalkyl, or a saturated 5- or 6-membered heterocyclic ring containing at least one heteroatom independently selected from N and O, said ring being optionally substituted with one or more substituents independently selected from halogen, C1-6 alkoxy, oxo, or C1-6 alkyl; R9 and R10 each independently represents an H or C1-6 alkyl atom; or a salt acceptable for pharmaceutical use thereof. Claim 28: A process for the preparation of a compound according to claim 1 or salt acceptable for pharmaceutical use thereof characterized in that it comprises: (a) the reaction of a compound of formula (3) wherein w, x, y, zy B have the values defined in claim 1, with a compound of formula (4), wherein p is in accordance with claim 1 and A is in accordance with claim 1 or a protected derivative thereof, and LG is a leaving group, or (b) the reaction of a compound of formula (5) wherein p, w, x, y, and Z have the values defined in claim 1 and A is in accordance with claim 1 or a protected derivative thereof, with an aldehyde compound of formula (6) wherein D, n, and R have the values defined in claim 1, or (c) the reaction of a compound of the preceding formula (5) with a compound of formula (7) wherein D, n and R have the values defined in claim 1, and LG is a suitable leaving group and optionally following (a), (b) or (c): converting a compound of formula (1) into another compound of formula (1); remove the protective group (s), if any, and / or form a salt acceptable for pharmaceutical use. |
| priorityDate | 2005-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.